Study of CYH33 in Combination With Olaparib an Oral PARP Inhibitor in Patients With Advanced Solid Tumors.

Phase 1

Terminated

• Conditions: Ovarian Cancer; Solid Tumor; Prostate Cancer; Breast Cancer; Endometrial Cancer
• Interventions: Drug: CYH33

• Registration Number: NCT04586335
• Lead Sponsor: Haihe Biopharma Co., Ltd.

Brief Summary

The purpose of this study is to assess the safety, tolerability and preliminary efficacy of CYH33 in combination with olaprib in patients with DDR gene mutations and/or PIK3CA mutations, in patients who have progressed on prior PARP inhibitor, and in patients with recurrent high grade serous ovarian, fallopian tube, or primary peritoneal cancer who are platinum resistant or refractory. The study will assess if this combination will optimize anti-tumor activity, block tumor growth and overcome the resistance to PARP inhibitor treatment. The study consists 2 parts. In Part 1 dose escalation, the objective is to determine the maximum toleration dose (MTD) of the combination. The final recommended phase 2 dose (RP2D) of CYH33 in combination with olaparib will be based on the totality of an overall assessment of available safety, tolerability, pharmacokinetics (PK), pharmacodynamics (PD), and preliminary efficacy which could be the MTD or a dose level lower in specific cohorts of patients. In Part 2 dose expansion, the main objective is to evaluate the efficacy at RP2D.

Detailed Description

DNA damage repair (DDR) pathways can modulate cancer risk, progression and therapeutic responses. Germline mutations in genes encoding key players in the DNA-damage response (DDR), including BRCA1, BRCA2,BLM, FANCA, TP53, RAD51C, and MSH2, result in cancer susceptibility syndromes, in part because failure to adequately protect the genome against endogenous and exogenous sources of DNA damage results in the accumulation of oncogenic mutations. The mechanistic rationale for the combination of PI3K and PARP inhibitors is that PI3K inhibition leads to a downregulation of BRCA1/2 proteins, which increase the degree of HRR deficiency CYH33 is a novel, highly potent and selective inhibitor of phosphatidylinositol 3-kinase αsignificantly inhibited the activities of wild-type and mutant PI3Kα kinase as well as the specific mutant of E542K, 1047R or E545K, On July13, 2018, a Phase I first-in-human dose escalation and expansion single-agent study of CYH33 (CYH33-101) started in China (ClinicalTrials.gov identifier: NCT03544905) identify the MTD of CYH33 single agent was 40 mg. The most common treatment related adverse events (\>5%) of Grade 3 was hyperglycemia. No treatment-related Grade 4 adverse event or death was reported in the ongoing trial by the cut-off date. In this combination study will assess if this combination will optimize anti-tumor activity, block tumor growth and overcome the resistance to PARP inhibitor treatment. The study consists 2 parts. In Part 1 dose escalation, the objective is to determine the maximum toleration dose (MTD) of the combination. The final recommended phase 2 dose (RP2D) of CYH33 in combination with olaparib will be based on the totality of an overall assessment of available safety, tolerability, pharmacokinetics (PK), pharmacodynamics (PD), and preliminary efficacy which could be the MTD or a dose level lower in specific cohorts of patients. In Part 2 dose expansion, the main objective is to evaluate the efficacy at RP2D.

Study Timeline

• Study First Submitted: 2020-08-25
• Study Start: 2020-09-28
• Study First Submitted QC: 2020-10-07
• Study First Posted: 2020-10-14
• Primary Completion: 2023-02-15
• Study Completion: 2023-02-15
• Status Verified: 2024-03
• Last Update Submitted: 2024-03-20
• Last Update Posted: 2024-03-21

Recruitment & Eligibility

• Status: TERMINATED
• Sex: All
• Target Recruitment: 24

Inclusion Criteria

Patients eligible for inclusion in this study have to meet all of the following criteria:

1. Provide informed consent voluntarily.

2. Male and female patients ≥ 18 years of age (or having reached the age of majority according to local laws and regulations, if the age is > 18 years).

3. Patients with advanced solid tumor who have failed at least one line of prior systemic therapy or for whom standard therapy do not exist and meet the following eligibility for the corresponding part of the study:

   1. Patient must have a histologically or cytologically confirmed diagnosis of advanced recurrent or metastatic solid tumor.

   2. At least one measurable lesion as per RECIST 1.1. (Ovarian cancer participants must have measurable disease by RECIST 1.1 criteria or evaluable cancer via CA125 GCIG criteria; Prostate cancer participants must have measurable disease by RECIST 1.1 criteria or evaluable cancer via PSA response).

   3. Population eligibility:

      • Patients eligible for Part 1 dose escalation: Advanced solid tumors with any DDR gene 1) or PIK3CA 2) mutation who have failed or cannot tolerate standard treatment or currently have no standard treatment.

      • Patients eligible for Part 2 dose expansion:

        • Cohort 1: Advanced solid tumors with any selected DDR3) gene mutation
        • Cohort 2: Advanced solid tumors with PIK3CA hotspot mutation
        • Cohort 3: Advanced high grade serous ovarian, fallopian tube or primary peritoneal cancer patients with acquired PARP inhibitor resistance4)
        • Cohort 4: Advanced solid tumors with any selected DDR3) gene mutation with acquired PARP inhibitor resistance4).
        • Cohort 5: Platinum resistant/refractory5) recurrent high grade serous ovarian, fallopian tube, or primary peritoneal cancer.

4. Availability of tumor tissue sample (either fresh tumor biopsy or archival tumor tissue sample) or blood samples.

5. Eastern Cooperative Oncology Group (ECOG) performance status ≤ 1.

Key

Exclusion Criteria

Patients eligible for this study must not meet any of the following criteria:

1. Patient has received any anticancer therapy (including chemotherapy, targeted therapy, hormonal therapy, biotherapy, immunotherapy, or other investigational agents.) within 28 days or 5 times of half-lives (whichever is shorter) prior to the first dose of the study treatment or who have not recovered from the side effect of such therapy.
2. Patients with contraindication to olaparib treatment or who did not tolerate olaparib previously.
3. Patients who had prior treatment with PARP inhibitor, PI3Kα inhibitor, AKT inhibitor or mTOR inhibitor (Part 2 dose expansion cohort 1& 2 only).
4. Radical radiation therapy (including radiation therapy for over 25% bone marrow) within 4 weeks prior to the first dose of the investigational product or received local palliative radiation therapy for bone metastases within 2 weeks.
5. Any toxicities from prior treatment that have not recovered to baseline or ≤ CTCAE Grade 1 before the start of study treatment, with exception of hair loss.
6. Patients with an established diagnosis of diabetes mellitus including steroid-induced diabetes mellitus.
7. Major surgery or had significant traumatic injury within 28 days prior to the first dose of the investigational product or has not recovered from major side effects.

Study & Design

• Study Type: INTERVENTIONAL
• Study Design: SEQUENTIAL

Arm && Interventions

Group	Intervention	Description
CYH33 in Combination with Olaparib	CYH33	CYH33 in Combination with Olaparib; 20 mg CYH33 QD in combination with olaparib 300 mg BID. Additional dose levels of CYH33 at20 and 30 mg QD and CYH33 at 40 mg QD in combination with olaparib 200 mg BID will be evaluated.

Primary Outcome Measures

Name	Time	Method
Dose Limiting Toxicities (DLT)	12 months	Incidence rate of dose limiting toxicities (DLT) in the first cycle (of 28 days) of each investigated dose levels.
Tumor objective response rate (ORR)	38 months	Tumor objective response rate (ORR) defined as the sum of complete response (CR) and partial response (PR) as best reported by RECIST version 1.1.

Secondary Outcome Measures

Name	Time	Method
Disease control rate (DCR)	38 months	Disease control rate (DCR) defined as the sum of CR, PR and stable disease (SD) by RECIST version 1.1. - Progression Free Survival (PFS).
Pharmacokinetic measures - Cmax	12 months	Measure the maximum (peak) plasma concentration(s) of CHY33/olaparib
Pharmacokinetic measures - Tmax	12 months	Measure of time to reach maximum (peak) plasma concentration(s) following administration of CHY33/olaparib
Pharmacokinetic measures - Plasma concentration time Area Under the Curve	12 months	Measure the variation of CHY33/olaparib concentration in blood plasma as a function of time
Pharmacokinetic measures - CL/F	12 months	Measure apparent total clearance(s) of CHY33/olaparib from plasma after oral administration
Number of participants with treatment-related adverse events as assessed by CTCAE v5.0	38 months	Number, type, incidence, duration, severity and seriousness of adverse events (AEs) as assessed by CTCAE v5.0
Pharmacokinetic measures - terminal half- life (t1/2)	12 months	Measure elimination half-life of CHY33/olaparib, when administered in combination
Pharmacokinetic measures - Vz/F	12 months	Measure apparent volume of distribution during terminal phase after administration of CHY33/olaparib

Trial Locations

Locations (7)

Integrated Oncology Network PTY LTD; 🇦🇺 Brisbane, Queensland, Australia

UT Southwestern: Simmons Cancer Center; 🇺🇸 Dallas, Texas, United States

MD Anderson Cancer Center; 🇺🇸 Houston, Texas, United States

Scientia Cancer Centre; 🇦🇺 Sydney, New South Wales, Australia

Monash Cancer Centre; 🇦🇺 Melbourne, Victoria, Australia

Yale Cancer Center; 🇺🇸 New Haven, Connecticut, United States

Fudan University - Pudong Medical Center; 🇨🇳 Shanghai, Shanghai, China